(Q50303936)

2 March 2018

title

Oxytocin and vasopressin levels are decreased in the plasma of male schizophrenia patients. (English)

1 reference

2 March 2018

0 references

0 references

1 reference

8

1 reference

2 March 2018

author name string

Andrea Jobst

1

1 reference

2 March 2018

Sandra Dehning

2

1 reference

2 March 2018

Simone Ruf

3

1 reference

2 March 2018

Tobias Notz

4

1 reference

2 March 2018

Anna Buchheim

5

1 reference

2 March 2018

Kristina Henning-Fast

6

1 reference

2 March 2018

Dominik Meißner

7

1 reference

2 March 2018

Brigitta Bondy

9

1 reference

2 March 2018

Norbert Müller

10

1 reference

2 March 2018

Peter Zill

11

1 reference

2 March 2018

publication date

7 October 2014

1 reference

2 March 2018

published in

Acta Neuropsychiatrica

1 reference

2 March 2018

volume

26

1 reference

2 March 2018

issue

6

1 reference

2 March 2018

page(s)

347-355

1 reference

2 March 2018

Vasopressin-deficient rats exhibit sensorimotor gating deficits that are reversed by subchronic haloperidol

cites work

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Oxytocin, vasopressin, and the neurogenetics of sociality

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Antipsychotic drugs and plasma vasopressin in normals and acute schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Determinants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

"Theory of mind" in schizophrenia: a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Oropharyngeal regulation of water balance in polydipsic schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

The functional significance of social cognition in schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Effects of single dose intranasal oxytocin on social cognition in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Peripheral oxytocin is associated with reduced symptom severity in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Oxytocin in schizophrenia: a review of evidence for its therapeutic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Apomorphine stimulation of vasopressin- and oxytocin-neurophysins. Evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Effects of dopamine and dopamine-active compounds on oxytocin and vasopressin production in rat neurohypophyseal tissue cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Vasopressin--oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Menstrual cycle-related changes in plasma oxytocin are relevant to normal sexual function in healthy women

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Dendritic peptide release and peptide-dependent behaviours

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Sex differences in vasopressin and oxytocin innervation of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Oxytocin improves "mind-reading" in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Further neurochemical and behavioural investigation of Brattleboro rats as a putative model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Oxytocin increases trust in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Clonidine decreases plasma and cerebrospinal fluid arginine vasopressin but not oxytocin in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

Amperozide and clozapine but not haloperidol or raclopride increase the secretion of oxytocin in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

7 January 2021

Is Oxytocin an Anti-Schizophrenic Hormone?

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

7 January 2021

Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

7 January 2021

Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

7 January 2021

Sharing secrets: oxytocin and trust in schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

7 January 2021

Vasopressin (DDAVP) therapy in chronic schizophrenia: effects on negative symptoms and memory.

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2014.20

7 January 2021

Identifiers

DOI

10.1017/NEU.2014.20

1 reference

2 March 2018

1 reference

2 March 2018